Giandomenico Disabato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giandomenico Disabato has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Gianluigi Guida
Cardiology University Department, IRCCS Policlinico San Donato , Piazza Edmondo Malan, Milan 20097
22 shared publications Andrea Attanasio
University Cardiology, IRCCS Policlinico San Donato , Via R. Morandi 30, 20097, San Donato Milanese, Milanm
19 shared publications- Massimo Francesco Piepoli
Clinical Cardiology, IRCCS Policlinico San Donato , Milan
15 shared publications Massimo Piepoli
University Cardiology, IRCCS Policlinico San Donato , Via Morandi 30, San Donato Milanese 20097
6 shared publications- Antonia Camporeale
Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
5 shared publications - Pietro Spagnolo
Department of Radiology IRCCS Policlinico San Donato San Donato Milanese Italy
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Impaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva
Background: Anomalous Aortic Origin of a Coronary Artery (AAOCA) high‐risk anatomical features (intramural segment, acute take‐off angle, slit‐like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. Aims: We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. Methods: We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non‐ischemic risk (no‐IR) group. Non‐anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Results: Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no‐IR) and 45 controls. The IR group had a median IM length of 9 mm, take‐off angle of 31.9°, and a slit‐like or oval ostium. The no‐IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. Conclusions: High‐risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take‐off angle, and slit‐like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.
- 15 October 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Open AccessImpaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva
Background: Anomalous Aortic Origin of a Coronary Artery (AAOCA) high‐risk anatomical features (intramural segment, acute take‐off angle, slit‐like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. Aims: We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. Methods: We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non‐ischemic risk (no‐IR) group. Non‐anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Results: Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no‐IR) and 45 controls. The IR group had a median IM length of 9 mm, take‐off angle of 31.9°, and a slit‐like or oval ostium. The no‐IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. Conclusions: High‐risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take‐off angle, and slit‐like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.
- Open Access
- 23 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (38)
Epicardial Amyloidoma Mimicking Secondary Cardiac Lymphoma
- 23 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (38)
Open AccessEpicardial Amyloidoma Mimicking Secondary Cardiac Lymphoma
- 9 July 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (5) , 2381-2395
4D Flow MRI ‐Based Quantification of Tricuspid Regurgitation: A Possible Approach to Improve Measurement Repeatability
Purpose: To address limitations in tricuspid regurgitation (TR) quantification by magnetic resonance imaging (MRI) or transthoracic echocardiography (TTE), a new method is proposed to directly quantify TR volume (TR V ) using 4D Flow MRI with retrospective tricuspid valve (TV) annular tracking. Methods: Thirty patients with TR were prospectively enrolled. TR V was quantified using four MRI‐based methods: (i) indirect, (ii) direct (2D phase‐contrast), (iii) 4D Flow with a static TV plane, and (iv) 4D Flow with dynamic annular tracking. Reproducibility and agreement were assessed in terms of TR grading against standard MRI‐ and TTE‐based methods. Results: The dynamic 4D Flow method correlated strongly with all other MRI methods ( r = 0.77–0.81, p < 0.0001) but consistently yielded higher TR V values. Compared with the indirect method, it showed a Bland–Altman bias of 16 mL (limits of agreement: −19 to 51 mL), along with the highest agreement (intraclass correlation coefficient of 0.88). Agreement in TR severity grading was poor across methods (kappa ≤ 0.07), with dynamic 4D Flow classifying more cases as moderate or severe. Agreement with TTE was slight (kappa = 0.17, p = 0.27) with concordant TR grading in 50% of patients. Inter‐observer reproducibility was excellent ( r = 0.99, bias = 0.7 mL, kappa = 0.80). Conclusion: 4D Flow with dynamic TV tracking offers a reproducible and potentially more sensitive method for TR V quantification than conventional MRI techniques. Despite limited alignment with TTE, this technique may help overcome key imaging limitations and improve TR clinical evaluation, especially in complex cases.
- 9 July 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (5) , 2381-2395
4D Flow MRI ‐Based Quantification of Tricuspid Regurgitation: A Possible Approach to Improve Measurement Repeatability
Purpose: To address limitations in tricuspid regurgitation (TR) quantification by magnetic resonance imaging (MRI) or transthoracic echocardiography (TTE), a new method is proposed to directly quantify TR volume (TR V ) using 4D Flow MRI with retrospective tricuspid valve (TV) annular tracking. Methods: Thirty patients with TR were prospectively enrolled. TR V was quantified using four MRI‐based methods: (i) indirect, (ii) direct (2D phase‐contrast), (iii) 4D Flow with a static TV plane, and (iv) 4D Flow with dynamic annular tracking. Reproducibility and agreement were assessed in terms of TR grading against standard MRI‐ and TTE‐based methods. Results: The dynamic 4D Flow method correlated strongly with all other MRI methods ( r = 0.77–0.81, p < 0.0001) but consistently yielded higher TR V values. Compared with the indirect method, it showed a Bland–Altman bias of 16 mL (limits of agreement: −19 to 51 mL), along with the highest agreement (intraclass correlation coefficient of 0.88). Agreement in TR severity grading was poor across methods (kappa ≤ 0.07), with dynamic 4D Flow classifying more cases as moderate or severe. Agreement with TTE was slight (kappa = 0.17, p = 0.27) with concordant TR grading in 50% of patients. Inter‐observer reproducibility was excellent ( r = 0.99, bias = 0.7 mL, kappa = 0.80). Conclusion: 4D Flow with dynamic TV tracking offers a reproducible and potentially more sensitive method for TR V quantification than conventional MRI techniques. Despite limited alignment with TTE, this technique may help overcome key imaging limitations and improve TR clinical evaluation, especially in complex cases.
- 3 July 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may be influenced by sex-specific hormones and pathologies that need to be addressed to improve prevention and treatment. This expert consensus statement aims to provide a comprehensive roadmap for HF prevention and management across specific conditions affecting women during their life-course. Each section focuses on the impact of a specific female condition on CVD and how to prevent and manage HF in specific settings: 1. Pregnancy with a specific focus on how to deal with hypertensive disorders in the acute and chronic setting and how to prevent and treat Peripartum Cardiomyopathy (PPCM); 2. Gynecological conditions predisposing to HF, such as Polycystic Ovary Syndrome (PCOS), endometriosis, and the menopausal transition. Emphasis is placed on chronic inflammation, metabolic dysfunction, and the “window of opportunity” for Menopausal Hormone Therapy (MHT); 3. Cardio-Oncology: mitigating Cancer Therapy-Related Cardiac Dysfunction (CTRCD) in breast and gynecological cancers, focusing on female-specific cardiotoxicity profiles, the importance of subclinical detection of cardiac dysfunction and the implementation of cardioprotective strategies (ACE-inhibitors, Beta-blockers, SGLT2 inhibitors) during cardiotoxic treatments. Lifestyle interventions such as the DASH diet and exercise-based rehabilitation are highlighted as essential for maintaining cardiac reserve.
- 3 July 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may be influenced by sex-specific hormones and pathologies that need to be addressed to improve prevention and treatment. This expert consensus statement aims to provide a comprehensive roadmap for HF prevention and management across specific conditions affecting women during their life-course. Each section focuses on the impact of a specific female condition on CVD and how to prevent and manage HF in specific settings: 1. Pregnancy with a specific focus on how to deal with hypertensive disorders in the acute and chronic setting and how to prevent and treat Peripartum Cardiomyopathy (PPCM); 2. Gynecological conditions predisposing to HF, such as Polycystic Ovary Syndrome (PCOS), endometriosis, and the menopausal transition. Emphasis is placed on chronic inflammation, metabolic dysfunction, and the “window of opportunity” for Menopausal Hormone Therapy (MHT); 3. Cardio-Oncology: mitigating Cancer Therapy-Related Cardiac Dysfunction (CTRCD) in breast and gynecological cancers, focusing on female-specific cardiotoxicity profiles, the importance of subclinical detection of cardiac dysfunction and the implementation of cardioprotective strategies (ACE-inhibitors, Beta-blockers, SGLT2 inhibitors) during cardiotoxic treatments. Lifestyle interventions such as the DASH diet and exercise-based rehabilitation are highlighted as essential for maintaining cardiac reserve.
- 9 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (39) , 5765-5767
A natural experiment in the air: particulate matter and acute myocardial infarction subtypes during the COVID-19 pandemic
- 9 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (39) , 5765-5767
A natural experiment in the air: particulate matter and acute myocardial infarction subtypes during the COVID-19 pandemic
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (2) , 159-160
Gaps in epidemiology of cardiovascular diseases
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (2) , 159-160
Gaps in epidemiology of cardiovascular diseases
- 6 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (1) , 1-3
Quality of care and clinical outcomes in invasive and interventional cardiology
- 6 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (1) , 1-3
Quality of care and clinical outcomes in invasive and interventional cardiology
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (8) , 1207-1209
Quality of care and clinical outcomes in clinical pharmacotherapy
- 19 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (8) , 1207-1209
Quality of care and clinical outcomes in clinical pharmacotherapy